Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3</p

Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3</p

Supplementary Figure S1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

Validation of candidate FDA-approved drugs.</p

Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

List of primary hits</p

Supplementary Materials and Methods from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

Spheroid image analysis, 3D invasion image analysis and antibodies list.</p

Supplementary Figure S4 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

In vivo imaging of IMR-32 tumor growth in NB orthotopic mice.</p

Supplementary Figure S3 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

In vivo imaging of SK-N-BE(2) tumor growth in NB orthotopic mice.</p

Supplementary Figure S2 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

Cell cycle and clonogenic profiles after treatments with ponatinib and axitinib.</p